| Literature DB >> 34886592 |
Woo Sun Song1, Hye Won Park2, Moon Youn Oh3, Jae Young Jo4, Chae Young Kim5, Jung Ju Lee6, Euiseok Jung3, Byong Sop Lee3, Ki-Soo Kim3, Ellen Ai-Rhan Kim3.
Abstract
BACKGROUND: Due to increases in the number of infants born with younger gestational age (GA) and lower birth weight, the incidence of neonatal sepsis is increasing.Entities:
Keywords: Antibiotic sensitivity; Causative organism; Neonatal sepsis
Year: 2021 PMID: 34886592 PMCID: PMC9263424 DOI: 10.3345/cep.2021.00668
Source DB: PubMed Journal: Clin Exp Pediatr ISSN: 2713-4148
Characteristics of the study patients between the 2 phases
| Characteristic | Phase I (n=315) (1998–2007) | Phase II (n=426) (2008–2017) | |
|---|---|---|---|
| Gestational age | 31+3 (23+0–42+1) | 30+3 (22+3–40+0) | |
| <26 weeks | 40/315 (12.7) | 89/426 (20.9) |
|
| 26–35 weeks | 153/315 (48.6) | 197/426 (32.9) |
|
| ≥35 weeks | 122/315 (38.7) | 140/426 (32.9) | 0.099[ |
| Male sex | 173/315 (54.9) | 229/426 (53.8) | 0.753[ |
| Birth weight (g) | 1,468 (469–4,900) | 1,290 (282–4,125) | |
| <1,500 | 160/315 (50.8) | 246/426 (57.7) | 0.060[ |
| 1,500–2,500 | 58/315 (18.4) | 73/426 (17.1) | 0.652[ |
| ≥2,500 | 97/315 (30.8) | 107/426 (25.1) | 0.087[ |
| Delivery mode (cesarean section) | 191/315 (60.6) | 294/426 (69.0) | 0.018[ |
| Inborn | 226/315 (71.7) | 407/426 (85.4) |
|
| Multiple gestation | 30/315 (9.5) | 174/426 (27.5) |
|
Values are presented as median (range) or number (%).
Indicating chi-square test.
Boldface indicates a statistically significant difference with P<0.05.
Comparison of distribution of causative bacteria between the 2 phases
| Variable | EOS | LOS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Phase I (n=35) (1998–2007) | Phase II (n=17) (2008–2017) | OR (95% CI) | Phase I (n=324) (1998–2007) | Phase II (n=519) (2008–2017) | OR (95% CI) | ||||
| Gram-positive bacteria | 26 (74.3) | 8 (47.1) | 0.053[ | 0.308 (0.091–1.039) | 212 (65.4) | 428 (82.5) |
| 2.485 (1.801–3.428) | |
| CoNS | 11 (31.4) | 5 (29.4) | 0.882[ | 0.909 (0.257–3.218) | 114 (35.2) | 345 (66.5) |
| 3.652 (2.728–4.890) | |
|
| 4 (11.4) | 0 (0) | 0.290[ | - | 51 (15.7) | 57 (11.0) |
| 0.660 (0.440–0.991) | |
|
| 0 (0) | 1 (5.9) | 0.327[ | - | 5 (1.5) | 11 (2.1) | 0.551[ | 1.381 (0.476–4.013) | |
| 2 (5.7) | 2 (11.8) | 0.589[ | 2.200 (0.282–17.137) | 1 (0.3) | 4 (0.8) | 0.654[ | 2.509 (0.279–22.545) | ||
| Others[ | 9 (25.7) | 0 (0) |
| - | 41 (12.7) | 11 (2.1) |
| 0.149 (0.076–0.295) | |
| Gram-negative bacteria | 9 (25.7) | 9 (52.9) | 0.053[ | 3.250 (0.962–10.978) | 112 (34.6) | 91 (17.5) |
| 0.402 (0.292–0.555) | |
|
| 1 (2.9) | 2 (11.8) | 0.246[ | 4.533 (0.381–53.925) | 32 (9.9) | 29 (5.6) |
| 0.540 (0.320–0.911) | |
|
| 4 (11.4) | 1 (5.9) | 1.000[ | 0.484 (0.050–4.702) | 18 (5.6) | 9 (1.7) |
| 0.300 (0.133–0.676) | |
|
| 1 (2.9) | 2 (11.8) | 0.246[ | 4.533 (0.381–53.925) | 13 (4.0) | 12 (2.3) | 0.157[ | 0.566 (0.255–1.257) | |
|
| 0 (0.0) | 1 (5.9) | 0.327[ | - | 7 (2.2) | 17 (3.3) | 0.344[ | 1.534 (0.629–3.740) | |
|
| 2 (5.7) | 0 (0) | 1.000[ | - | 18 (5.6) | 3 (0.6) |
| 0.099 (0.029–0.338) | |
|
| 0 (0) | 2 (11.8) | 0.103[ | - | 9 (2.8) | 4 (0.8) |
| 0.272 (0.083–0.890) | |
|
| 0 (0) | 0 (0) | - | 6 (1.9) | 7 (1.3) | 0.576[ | 0.725 (0.241–2.175) | ||
|
| 1 (2.9) | 0 (0) | 1.000[ | - | 6 (1.9) | 2 (0.4) | 0.060[ | 0.205 (0.041–1.022) | |
|
| 0 (0) | 0 (0) | - | 3 (0.9) | 5 (1.0) | 1.000[ | 1.041 (0.247–4.385) | ||
| Others[ | 0 (0) | 1 (5.9) | 0.327[ | - | 0 (0.0) | 3 (0.4) | 0.289[ | - | |
Values are presented as number (%).
EOS, early-onset sepsis; LOS, late-onset sepsis; OR, odds ratio; CI, confidence interval; CoNS, coagulase-negative Staphylococcus.
Chi-square test.
Fisher extract test.
Others: Listeria monocytogenes, Streptococcus species (except S. agalactiae), Enterococcus faecium, Bacillus species, Clostridium clostridioforme, Micrococcus species.
Others: Haemophilus influenza, Chryseobacterium meningosepticum, Enterobacter agglomerans, Salmonella group C.
Boldface indicates a statistically significant difference with P<0.05.
Comparison of distribution of mortality between the 2 phases
| Microorganism | Phase I (1998–2007) | Phase II (2008–2017) | OR (95% CI) | |
|---|---|---|---|---|
| Mortality | 39/315 | 27/426 | ||
|
| 5/33 (15.2) | 7/31 (22.6) | 0.447[ | 1.633 (0.458–5.819) |
| ESBL-producing | 2/5 (40.0) | 5/7 (71.4) | ||
|
| 7/20 (35.0) | 2/3 (66.7) | 0.538[ | 3.714 (0.284–48.545) |
|
| 6/55 (10.9) | 3/57 (5.3) | 0.317[ | 0.454 (0.108–1.913) |
|
| 5/122 (5.0) | 3/125 (1.2) |
| 0.234 (0.055–0.997) |
|
| 4/14 (28.6) | 2/14 (14.3) | 0.648[ | 0.417 (0.063–2.768) |
|
| 3/22 (13.6) | 1/10 (10.0) | 1.000[ | 0.704 (0.064–7.742) |
| Mortality of EOS | 7/33 (21.2) | 5/17 (29.4) | 0.728[ | 1.548 (0.407–5.887) |
| Mortality of LOS | 32/282 (11.3) | 22/409 (5.4) |
| 0.444 (0.252–0.782) |
| Total mortality | 39/315 (12.4) | 27/426 (6.3) |
| 0.479 (0.286–0.801) |
Values are presented as number (%).
OR, odds ratio; CI, confidence interval; ESBL, extended spectrum β-lactamases; EOS, early-onset sepsis; LOS, late-onset sepsis.
Chi-square test.
Fisher extract test.
Boldface indicates a statistically significant difference with P<0.05.
Fig. 1.Comparison of causative agents of neonatal sepsis resulting in death. (A) Proportions of microorganisms related to death. (B) Comparison between the proportions of gram-positive and gram-negative organisms associated with mortality.
Analysis of associated factors for mortality
| Factor | Episodes | OR (95% CI) | |
|---|---|---|---|
| GA (wk) | 0.016[ | 0.496 (0.278–0.886) | |
| <37 | 50/554 (9.0) | ||
| ≥37 | 16/341 (4.7) | ||
| Birth weight (g) | |||
| <1,500 | 36/508 (7.1) | 0.706[ | 1.102 (0.666–1.823) |
| ≥1,500 | 30/387 (7.8) | ||
| <2,500 | 47/660 (7.1) | 0.627[ | 1.147 (0.659–1.998) |
| ≥2,500 | 19/235 (8.1) | ||
| Gram-positive bacteria | 23/674 (3.4) | <0.001 | 6.838 (4.014–11.649) |
| Gram-negative bacteria | 43/221 (19.5) | ||
| MRSA mortality rate | 6/66 (9.0) | ||
| ESBL[ | 9/41 (21.9) |
Values are presented as number (%).
OR, odds ratio; CI, confidence interval; GA, gestational age; MRSA, methicillin-resistant Staphylococcus aureus; ESBL, extended spectrum β-lactamases.
Chi-square test.
ESBL: 28 cases of Klebsiella pneumoniae, 12 cases of Escherichia coli, 1 case of Klebsiella oxytoca; infants with 6 cases of K. pneumoniae and 3 cases of E. coli died, respectively.
Comparison of antibiotics susceptibility of causative agents between the 2 phases
| Microorganism | Phase I (1998–2007) | Phase II (2008–2017) | OR (95% CI) | |
|---|---|---|---|---|
| Gram-positive bacteria | ||||
| Staphylococcus aureus | ||||
| Penicillin | 1/52 (1.9) | 2/57 (3.5) | 1.000[ | 1.855 (0.163–21.076) |
| Cefotaxime | 12/52 (23.1) | 8/12 (66.7) |
| 6.667 (1.707–26.042) |
| Oxacillin | 10/52 (19.2) | 33/57(57.9) |
| 5.775 (2.426–13.746) |
| CoNS | ||||
| Penicillin | 1/114 (0.9) | 0/350(0.0) | 0.246[ | 0.991 (0.974–1.008) |
| Cefotaxime | 3/105 (2.9) | 1/51 (2.0) | 1.000[ | 0.680 (0.069–6.704) |
| Oxacillin | 3/114 (2.6) | 10/350(2.9) | 1.000[ | 1.088 (0.294–4.025) |
| Gram-negative bacteria | ||||
| Klebsiella pneumoniae | ||||
| Gentamicin | 9/30 (30.0) | 26/31 (83.9) |
| 12.133 (3.528–41.729) |
| Cefotaxime | 6/30 (20.0) | 20/31 (64.5) |
| 7.273 (2.284–23.160) |
| Ceftriaxone | 6/30 (20.0) | 16/20 (80.0) |
| 16.000 (3.889–65.830) |
| Enterobacter cloacae | ||||
| Gentamicin | 5/20 (25.0) | 10/10 (100.0) |
| 0.250 (0.117–0.534) |
| Cefotaxime | 5/20 (25.0) | 8/10 (80.0) |
| 12.000 (1.885–76.376) |
| Ceftriaxone | 5/20 (25.0) | 5/6 (83.3) |
| 15.000 (1.397–161.045) |
| Escherichia coli | ||||
| Gentamicin | 5/14 (35.7) | 7/14 (50.0) | 0.704[ | 1.800 (0.396–8.182) |
| Cefotaxime | 7/13 (53.8) | 6/14 (42.9) | 0.568[ | 0.643 (0.141–2.938) |
| Ceftriaxone | 7/14 (50.0) | 2/5 (40.0) | 1.000[ | 0.667 (0.084–5.301) |
Values are presented as number (%).
OR, odds ratio; CI, confidence interval; CoNS, coagulase-negative Staphylococcus.
Chi-square test.
Fisher extract test.
Boldface indicates a statistically significant difference with P<0.05.